We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study.
- Authors
Islim, Abdurrahman I.; Lee, Jing X.; Mustafa, Mohammad A.; Millward, Christopher P.; Gillespie, Conor S.; Richardson, George E.; Taweel, Basel A.; Chavredakis, Emmanuel; Mills, Samantha J.; Brodbelt, Andrew R.; Jenkinson, Michael D.
- Abstract
Background: Sporadic multiple meningioma are uncommon. Population-based data suggests that these patients have a reduced overall survival when compared to patients with solitary meningioma. The aim of this study was to investigate the clinical outcomes in multiple and solitary meningioma. Methods: A single-center matched cohort study (2008–2018) was performed. Patients with synchronous multiple meningioma at presentation, with no history of prior intracranial radiation, concurrent hormone replacement therapy or features of NF2-schwannomatosis were included. Eligible patients were matched 1:1 to patients with solitary meningioma. Outcomes of interest were occurrence of an intervention, recurrence, new meningioma development and mortality. Results: Thirty-four patients harboring 76 meningioma at presentation were included. Mean age was 59.3 years (SD = 13.5). Thirty-one (91.2%) were female. The median number of meningioma per patient was 2 (range 2–6). Eighteen patients (52.9%) were symptomatic at presentation. Median overall follow-up was 80.6 months (IQR 44.1–99.6). Compared to patients with a sporadic meningioma, there was no difference in intervention rates (67.6% vs 70.6%, P = 0.792). Eight patients (34.8%) with a multiple meningioma had a WHO grade 2 meningioma compared to 7 (29.2%) with a solitary meningioma (P = 0.679). Median recurrence-free survival was 89 months (95% CI 76–104) with no difference between the two groups (P = 0.209). Mean overall survival was 132 months (95% CI 127–138) with no difference between the two groups (P = 0.860). One patient with multiple meningioma developed two further new meningioma 36 months following diagnosis. Conclusion: Sporadic multiple meningioma may not have worse clinical outcomes. Management of patients with sporadic multiple meningioma should be tailored towards the symptomatic meningioma or high-risk asymptomatic meningioma.
- Subjects
MENINGIOMA; TREATMENT effectiveness; SURVIVAL rate; OVERALL survival; HORMONE therapy
- Publication
Journal of Neuro-Oncology, 2023, Vol 161, Issue 2, p287
- ISSN
0167-594X
- Publication type
Article
- DOI
10.1007/s11060-022-04184-4